The worldwide proliferation of life-threatening metallo-β-lactamase (MBLs)-producing Gram-negative bacteria is a serious concern to public health. MBLs are compromising the therapeutic efficacies of β-lactams, particularly carbapenems, which are last-resort antibiotics indicated for various multidrug- 
Introduction
The alarming spread of antimicrobial resistance (AMR) presents a major challenge to public health worldwide 121, 135 . The dissemination of AMR is spearheaded by increasing world trade, rising human and animal populations, economic factors, changing climatic conditions and air travel, which are breaking down geographical borders between countries and continents, exposing humans and animals to diverse kinds of infections 81 . The immense clinical benefits obtained from antimicrobials in the management of infectious diseases were eroded by the emergence of AMR in pathogens, a few years after their introduction and adoption into clinical medicine 26, 134 . As new antibiotics have been discovered and introduced into clinical use, a similar resistance cycle has ensued: resistance to cephalosporins due to the expression of extended spectrum β-lactamases (ESBLs); carbapenem resistance due to carbapenemases; resistance to colistin due to plasmid-mediated mcr-1 gene and chromosomal mutations; tigecycline resistance due to chromosomal mutations 122, 123 .
Gram-negative bacteria develop resistance to β-lactams through different mechanisms 111 , including the production of enzymes called β-lactamases that hydrolyze the β-lactam ring. Resistance can also be developed through modification(s) of the normal penicillin-binding proteins (PBPs), reduced porin expression leading to impermeability of the outer membrane and active antibiotics expulsion from the bacteria through efflux pump systems. The presence of one or more of these mechanisms in microorganisms can lead to β-lactam resistance 97, 98, 111, 152 .
Bacterial β-lactamases are members of an enzyme family capable of impairing the efficacy of β-lactam antibiotics such as penicillins, cephalosporins, monobactams, and carbapenems ( Figure 1) 14, 58 by hydrolysing their β-lactam rings 136 . There are two globally accepted classification schemes for β-lactamases. The first scheme is based on the amino-acid sequence of the enzyme and comprises four classes i.e., class A, B, C and D. The second scheme is based on the enzyme's functionality or substrate and includes three major groups: Group 1 or cephalosporinases (Class C), Group 2 or serine β-lactamases (Classes A and D), and Group 3 or metallo-β-lactamases (Class B). Each of these groups are further sub-divided into several different sub-groups 20, 137 . Classes A, C and D β-lactamases possess the amino acid serine at their active site and are thus known as serine β-lactamases (SBLs) while Ambler class B β-lactamases contain one or two zinc ions at their active site, and are thus called metallo-β-lactamases (MBLs).
The production of class B β-lactamases in bacteria, together with other resistancemechanisms, has narrowed down treatment options for infections caused by these pathogens 21 . One approach for treating β-lactamase-producing bacterial infections is by combining existing β-lactam antibiotics with β-lactamase inhibitors 22 . β-lactam-β-lactamase inhibitor combinations resulted in the restoration of β-lactam antibiotics' activity against β-lactamase-producing bacteria. Such combination drugs currently approved by the FDA and available for clinical treatment 22 Invariably, the increasing worldwide prevalence of MBLs is a major threat to global healthcare, affecting both community and hospital settings 39, 55, 74, 133 . Mortality rates of up to 50% have been reported for carbapenem-resistant Enterobacteriaceae (CRE), including MBL-positive MBL infections 37, 77 . Over the last decade, the prevalence of these drug-resistant bacterial infections has been increasing, affecting over a million patients worldwide. This has led to prolonged hospitalization, longer terms of disability, increased healthcare-associated costs, higher mortalities etc. 39, 129, 185 . The World Health Organization (WHO) recently listed CRE pathogens as "critical priority pathogens" for which novel and efficient antibiotics are required urgently 189 .
The absence of clinical MBLIs for MBL-mediated drug-resistant infections, particularly involving CREs, makes this class of ϐ-lactamases especially important in infectious diseases. Hence, this review aims to map out advances made so far in finding MBLIs that can fight MBL producers and point out challenges involved in designing clinically useful MBLIs.
Metallo-β-lactamases (MBLs)
MBLs confer resistance to all β-lactams except monobactams by using their active-site zinc ions to activate a nucleophilic water molecule, which opens the β-lactam ring (through hydrolysis) and render it ineffective 182 . For many decades, MBLs were considered to be clinically irrelevant enzymes that were chromosomally encoded in non-pathogenic organisms 85, 95, 143, 179 . This situation has changed with the increasing spread of NDM-, VIM-and IMP-mediated AMR in Gram-negative pathogens, including Enterobacteriaceae. The above-mentioned enzymes are carried on chromosomes or plasmids and located on mobile genetic cassettes inserted into integrons (IMP & VIM) and/or bracketed by composite transposons (NDM) 30, 87 . Transposons are DNA segments capable of moving to different positions in the genome of a single cell while Integrons are key elements that can shuttle genes between integrons on plasmids, therefore allowing the plasmids to transfer genetic material to different bacteria 11 . These mechanisms mediate the spread of MBL-mediated resistance worldwide. A typical example is the dissemination of NDM-1 MBL, first isolated from a Swedish patient transferred from India 193 in 2008, worldwide in diverse Enterobacteriaceae species. And the incidence rate continues to grow 193 .
MBLs are divided into three (3) subclasses namely, B1, B2 and B3 (Table 1) , based on differences in their primary zinc coordination shell and their amino acid sequence. Sequence identity between subclass B1 and B2 enzymes ranges from 14 to 24% while sequence identity between subclass B3 and both subclasses B1 and B2 enzymes ranges from 2% to 14% 73 . Subclass B1 possesses a binuclear active site, within which either one or two zinc ions can exist. B1 binds one zinc ion (Zn1) with three Histidine residues (H116, H118, H196) and a second zinc ion (Zn2) with three different residues, including a Cysteine (D120, C221, H263) in particular. Subclass B1 is a clinically relevant and notorious MBL, comprising the largest number of MBLs located on plasmids. Thus, it is more likely to spread to other organisms to cause ϐ-lactam-resistant clinical infections 43 . 71 and β-Lactamase Database (BLDB), are summarized in Table 1 113 .
MBLs were detected from diverse species of organisms as shown in Table 1 . However, subclass B2
was mostly detected from Aeromonas spp. Interestingly, most MBLs were initially identified in Europe (France, Germany, Denmark, UK, Italy etc.). Africa had the least discovered number of these MBLs, not because of their absence in the continent but rather a lack of proper awareness, skilled personnel, resistance diagnosis and surveillance system. Class B3 also contained the enzyme Adelaide Imipenemase (AIM) that is plasmid-borne (Table 1) .
Phylogenetic Analysis and Metadata of MBLs
All the reported MBLs together with their available metadata are illustrated on a phylogenetic tree to demonstrate the associated characteristics of the different sub-classes: B1, B2 and B3. Protein sequences of all reported MBLs (Table 1) were downloaded from GenBank using their accession numbers. They were then respectively aligned using default parameters/settings of classical sequence analysis with the CLC Genomics Workbench (version 10.1.1) software to generate an aligned file. The created aligned file was used to draw the maximum likelihood phylogenetic tree to infer the evolutionary relationship using optimized parameters as follows: construction method: UPGMA; nucleotide substitution model: Jukes cantor; protein substitution model: WAG; transition/transversion ratio: 2; estimate substitution rate: Yes; number of substitution rate: 4; perform bootstraps analysis: Yes;
replicates: [1000] . Metadata associated with the aligned sequences ( Table 1) was imported to provide a comprehensive analysis of the generated phylogenetic tree. TEM-1 (Ambler class A β-lactamase) was used as the outgroup (reference) to root the tree to enable easy configuration of the phylogenetic distance between the MBL enzymes on the branches. The circular version of the tree is shown in Figure 2 .
The phylogenetic analysis depicted a clear distinction between sub-classes B1 and B3 as reported in the literature 56, 57 , where they were more phylogenetically related to each other compared to B2 ( Figure   2 ). Metadata analysis provided a deeper insight into the associated characteristics and distinctions between all the sub-classes. Specifically, sub-classes B1 and B3 MBLs act on a broad spectrum of β-lactam antibiotics while class B2 MBLs have a narrower β-lactam spectrum, affecting only carbapenems. This diversity further complicates the management of CREs in the clinical setting making it a huge challenge for a single inhibitor to act efficiently on all MBLs sub-groups. The metadata also indicated that B2 and B3 were mostly chromosomal while B1 was both plasmid-and chromosomallymediated. Even though SPM was phylogenetically clustered with sub-class B2, the metadata differentiated them into a distinct sub-group as illustrated in Figure 2 , reiterating the importance of visualizing phylogenetic structures in relation to their metadata 3 .
Novel MBLs recently discovered through genomics and metagenomics
The advent of modern techniques such as next/whole-genome sequencing as a diagnostic tool in clinical microbiology has led to the discovery of novel genes and diverse mechanisms of drug resistance that could have been otherwise impossible to find using conventional diagnostic methods.
Berglund and collaborators in 2017 12 assumed that there is an existence of a large number of unexplored reservoir of uncharacterized MBLs. Hence, with the aid of new computational methods based on hidden Markov's model, they identified novel MBL genes of subclass B1, from bacterial genomes, plasmids and metagenomic data. The findings predicted the existence of 76 novel genes of subclass B1. Based on the evolutionary origin of the genes, a phylogenetic analysis revealed that the subclass B1 could be differentiated into five groups (subclass B1-1 to B1-5). However, these recently discovered novel MBLs are not listed in Table 1 due to the lack of proper nomenclature and very scant information or metadata (i.e. no information on country, bacteria isolated from and genetic location).
These current findings by Berglund et al. (2017) , thus echoes the diversity and proliferation of MBLs as well as their possible threat to clinically available antibiotic options, cautioning scientist to be prepared for the challenges that may occur in the future regarding the control and treatment of these life-threating pathogens. Therefore, there is an urgent need to find efficient and effective MBLIs to overcome this global scourge.
Metallo-β-Lactamase Inhibitors (MBLIs)
β-lactam/β-lactamase inhibitor/adjuvant combinations have been developed and are in clinical use for the treatment of infections caused by SBLs, while others are in clinical trials 22 (Tables 2 and 3 ). These molecules fail to inhibit MBLs, thus urgently necessitating the development of inhibitors that target bacterial metallo-enzymes.
In areas with increasing proliferation of MBL-positive CREs, clavulanic acid, sulbactam, tazobactam, and avibactam, which are all serine-based β-lactamase inhibitors in clinical use (Table 2) , do not provide much benefit 22 . One approach to overcome the effects of MBLs is by designing specific inhibitors that can be co-administered with β-lactam antibiotics. Studies have been executed in this direction where a number of potent MBLIs have been identified, although none of these inhibitors has thus far reached clinical trials 104 . The general challenge in identifying and developing broad-spectrum MBLIs stems from the structural and mechanistic differences within the three sub-classes of MBLs.
Reported MBLI groups include thiol and thioester derivatives 166 , tetrazoles and hydroxamates 170, 184 sulfonic acid derivative s 41 , β-lactam analogues derivatives 23 , pyrroles-based inhibitors 107 , pyridine dicarboxylates 67 , peptides 17 natural products 127 , nucleic acid 153 , and metal chelators 154 . (Table 4 ). 125 .
Thiomandelic acid and derivatives were also found to be broad-spectrum MBLIs 109 . During the establishment of a library of thiomandelic acid analogues, Mollard and coworkers (2001) realized that thiols with a carboxylic moiety improved the efficacy of the compounds while the thiol group remained essential for the inhibitory effect. This was revealed by the substitution of thiol group with a bromo, hydroxyl, or amidoxime function, and it was found that the thiomandelic acid analogues failed to inhibit the activity of BcII MBL 109 . The racemic-thiomandelic acid exhibited greater inhibitory activity with a Ki value of 0.09 µM than the isomer-thiomandelic acid with Ki of 1.28 µM against BcII enzyme. MBL members of sub-class B1 were the most largely inhibited by thiomandelic acid and thiol-containing compounds; however, they were also effective against sub-class B2 and B3 94, 109, 166 .
Captopril derivatives, L-and D-captopril, were investigated for their inhibitory activity against MBL by Cyclic boronates are broad-spectrum β-lactamase inhibitors, which act against both serine-and zincbased β-lactamases, as well as target penicillin-binding proteins (PBP) 19 . This group of inhibitors was found to be active against sub-class B1 MBLs, providing an avenue for the development of dual-action inhibitors targeting both serine-and zinc-based β-lactamases, in addition to possessing antimicrobial activity by inhibiting PBPs. hydroxamates and oximes were prepared and tested against MBLs to evaluate their inhibitory activity.
Pyrrole-based inhibitors
The reverse hydroxamates were found to inhibit the GIM-1 MBL 45 whereas 6-alkylidene-2-substituted penam sulfones, and cyclobutanone derivatives of β-lactams were also reported as inhibitors of Bla2
and IMP-1 respectively 6,72 . β-lactam analogues inhibitors are likely to be broad spectrum, extending their activity to both classes of β-lactamases (serine-and zinc-based β-lactamases).
Metal Chelators
The use of zinc-chelating agents is an approach for inhibiting MBLs as MBLs require one or two zinc ions in their active site to hydrolyze β-lactams 36 . The utilization of zinc-chelating agents will interfere with the functionality of the zinc ions by sequestering them from the active site of MBLs, thus reducing the MBLs' activity 154 .
Several metal chelators with a strong affinity for zinc ions have shown inhibitory effects against different classes of MBLs. Docquier et al. (2003) demonstrated that VIM-2 was susceptible to inactivation by metal chelators, indicating that the zinc ions of this enzyme were probably loosely bound and thus subject to easy sequestration by zinc-chelating agents 36 . Among the numerous metal-chelating agents, ethylene diamine tetra-acetic acid (EDTA) has been widely reported as a potential MBLI. It exhibited an IC50 of 27.9 μM for the acquired IMP-1 enzymes 28 . In addition, this molecule possesses essential antimicrobial properties such as potentiation of the activity of other antibiotics through the disruption of the outer membrane of Gram-negative bacteria, as well as the neutralization of enzymes and toxins produced by organisms. Due to its toxicity, EDTA was not considered suitable for therapeutic use 196 . In 2010, Nobumasa Aoki et al. evaluated the efficacy of calcium-EDTA (Ca-EDTA) as an MBLI, which was found to be less toxic than EDTA for in-vivo assays using murine models. They discovered that imipenem's activity was restored in the presence of Ca-EDTA in all the tested P. aeruginosa isolates producing IMP and VIM enzymes, but failed to restore its activity in all the non-MBL-producing strains 196 . An in-vivo study demonstrated significant reduction in bacterial colony forming units (CFU) in the lung of infected mice when treated in combination with imipenem and Ca-EDTA. These findings suggest that Ca-EDTA could be used clinically due to its lesser toxic effect compared to EDTA 196 .
Dipicolinic acid is another metal-chelating agent that demonstrated good inhibitory effect against members of the three MBL classes namely, CcrA, CphA and L1 139 . Pyridine 2,4-dicarboxylic acid is also one of the numerous zinc-chelating agents that inhibited CphA 67 . A natural fungal product, AMA, which is structurally similar to EDTA, was identified as a potent inhibitor of NDM-1 and VIM-2 in 2014 78 . Irreversible inhibition was observed with AMA after its removal by gel filtration; nevertheless, the activity of the sub-class B1 enzyme was restored by adding an excess ZnSO 4, suggesting that AMA acts by metal sequestration. The observed survival rates of infected mice with a lethal dose of K.
pneumoniae strains producing NDM-1 was 95%, demonstrating that AMA prevented the hydrolysis of the β-lactam antibiotic in vivo 78 . This potent MBLI also showed less toxicity compared to EDTA. In The greatest challenge to the clinical use of metal chelators is that they also inhibit human metalloenzymes such as matrix metallo-proteinase, carbonic anhydrase and carboxypeptidases necessitating further investigations into their systemic effect on living tissues.
Conclusion and future perspectives
This review elucidates the diversity, and alarming dissemination of MBLs causing carbapenem resistance. It is known that the discovery of efficient MBLIs is difficult, in part, due to the flexible active sites of the multiple enzymes and the challenges associated with targeting metallo-enzymes. Therefore, the hunting of MBLIs should ideally be specific to bacterial metallo-enzymes and circumvent other zinccontaining enzymes in humans. Inhibitors should either mimic the structure of the enzymes' substrates or allosterically inhibit the activity of this enzyme. The other challenge is that the performance of these inhibitors varied from one subclass to another. Worse still, structural variations are known to occur within the same subclass, rendering the discovery and development of MBLIs more challenging.
Particularly, it will be a great feat to identify compounds that inhibit plasmid-encoded subclass B1
enzymes, which includes the most widespread and clinically important MBLs.
Emphasis needs to be placed on designing and developing MBLIs to extend their inhibitory spectrum to the three classes of MBLs, restore the efficacy of available β-lactam antibiotics and improve their pharmacological properties. Moreover, genomic data generated with current methods such as next/whole genome sequencing, coupled with phylogenetics and metadata are currently one of the tools that give valuable insight into the identification and characterization of MBLs. They also help elucidate the global spread or epidemiology of these MBLs. These modern methods also have a quick turnaround time compared to traditional ones and should be explored to find lasting solutions to this menace. In-depth analysis and optimization of MBLIs, employing a multidisciplinary research approach involving advanced computational simulations, biochemical, microbiological, bio-informatics and animal studies to develop novel metallo-β-lactamase inhibitors are needed to precipitate the development of efficient clinical MBLI adjuvants.
